Search company, investor...

Bolder BioTechnology

bolderbio.com

Stage

Grant - II | Alive

Total Raised

$3.5M

Last Raised

$1.9M | 14 yrs ago

About Bolder BioTechnology

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

Headquarters Location

2425 55th Street Suite 210

Boulder, Colorado, 80301,

United States

303-420-4420

Missing: Bolder BioTechnology's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Bolder BioTechnology's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Bolder BioTechnology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Bolder BioTechnology is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Bolder BioTechnology Patents

Bolder BioTechnology has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Transcription factors
  • Cytokines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/19/2016

1/25/2022

Clusters of differentiation, ACE inhibitors, Cytokines, Monoclonal antibodies, Prodrugs

Grant

Application Date

9/19/2016

Grant Date

1/25/2022

Title

Related Topics

Clusters of differentiation, ACE inhibitors, Cytokines, Monoclonal antibodies, Prodrugs

Status

Grant

Latest Bolder BioTechnology News

Bolder BioTechnology says MS drug candidate could be used for COVID-19

Aug 26, 2020

Share this: PUBLISHED: | UPDATED: August 25, 2020 at 5:38 p.m. Eight-person drug development outfit Bolder BioTechnology Inc. said its multiple sclerosis drug candidate showed early promise as a potential treatment for COVID-19. The Boulder company said Tuesday that the drug candidate designated as BBT-032 was able to inhibit 85% to 100% of COVID-19 viral replication at low doses when tested on healthy cells within a petri dish. BBT-032 is part of a class of drugs known as interferons, which generally induce cells to create proteins that fight viral infections and reduce inflammation caused by diseases like AIDS, hepatitis C and certain types of cancer. Bolder BioTechnology president Joe Cox told BizWest that the drug could be used both as a treatment for early-stage COVID patients to slow down the virus’ replication and as a preventative measure for medical workers treating patients. If approved for clinical study by the U.S. Food and Drug Administration, Bolder BioTechnology would be the only U.S. company researching interferons as a treatment for COVID-19. While COVID-specific clinical studies of the drug have occurred in Hong Kong and China, the U.S. National Institutes of Health currently recommends against using interferons for severe COVID patients because the drug’s side effects of enhancing flu-like symptoms could further harm critical-care patients. The NIH also says interferons were ineffective against severe cases of earlier coronaviruses such as MERS and SARS. Cox said the company plans to file an investigational new drug application with the FDA by the end of the year which, if approved, would allow the company to start testing the drug on healthy volunteers in a Phase I clinical trial. The earliest-case timeline would be if the FDA grants a narrow, emergency use authorization for the drug midway through 2021, he said. It’s possible that authorization may come after the world’s largest drug companies land approval for a myriad of COVID vaccines currently in late-stage trials, but Cox said BBT and interferons like it could serve as off-the-shelf treatments for future diseases because their mechanisms of action may fight off multiple types of ailments. “The beauty of what this protein does, stimulating your cells to resist viruses… it works against this particular virus, but it should work against lots of different viruses,” he said. © 2020 BizWest Media LLC

Bolder BioTechnology Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Bolder BioTechnology Rank

Bolder BioTechnology Frequently Asked Questions (FAQ)

  • Where is Bolder BioTechnology's headquarters?

    Bolder BioTechnology's headquarters is located at 2425 55th Street, Boulder.

  • What is Bolder BioTechnology's latest funding round?

    Bolder BioTechnology's latest funding round is Grant - II.

  • How much did Bolder BioTechnology raise?

    Bolder BioTechnology raised a total of $3.5M.

  • Who are the investors of Bolder BioTechnology?

    Investors of Bolder BioTechnology include Bolder BioTechnology and National Institute of Neurological Disorders and Stroke.

  • Who are Bolder BioTechnology's competitors?

    Competitors of Bolder BioTechnology include Aerie, Longevica, Advaxis, Paratek Pharmaceuticals, Cyclacel Pharmaceuticals, Arcadia Biosciences, PDS Biotechnology, Keryx Biopharmaceuticals, Zymeworks, Raptor Pharmaceutical Corp. and 29 more.

Compare Bolder BioTechnology to Competitors

A
Arisyn Therapeutics

Arisyn Therapeutics Inc. is a biotechnology company focused on the development of first in class inhibitors of infectious disease and cancer. Arisyn possesses a portfolio of small molecule compounds that will be developed to treat Human Immunodeficiency Virus-Type 1 (HIV-1), Human Immunodeficiency Virus-Type 2 (HIV-2), Human T-Lymphotropic Virus-Type 1 (HTLV-1), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Herpes Simplex Virus-Type 2 (HSV-2). Arisyn will perform all necessary studies required to develop these therapeutic agents through Phase 1 and Phase 2 human clinical trials.

S
Spaltudaq

Spaltudaq Corporation, a privately-held biotechnology company based in Seattle, is focused on developing therapeutic antibodies for the treatment of inflammation, infectious disease and cancer. Our technology harnesses the power of the human immune system to identify tumor-specific or pathogen-specific monoclonal antibodies from human tissue samples.

A
ATNT

ATNT is a biotech company which develops cross-disciplinary engineering methods, to find the most effective molecular targets for treatment of complex human disorders.

Q
Qwell Pharmaceuticals

Qwell Pharmaceuticals is a biotechnology company focused on small molecule development primarily for oncology indications.

A
Alethia BioTherapeutics

Alethia BioTherapeutics is a biotechnology company that develops monoclonal antibody therapeutics to clinically relevant targets identified using its STAR discovery technology.

A
Anaborex

Anaborex Anaborex is an early stage biotechnology company developing drugs for the treatment of the wasting syndrome many cancer patients experience towards the late stages of their disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.